Agrow is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. Please do not redistribute without permission.

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Monsanto/Evogene extend R&D pact

Monsanto and the Israeli biotechnology company, Evogene (Rehovot), have again extended their research agreement on the development of improved crops. The five-year collaboration in 2008 on the identification of genes related to yield, environmental stress and fertiliser utilisation in maize, soybeans, cotton and canola, was prolonged by a year in late 2011 (Agrow No 630, p 23). That deal has now been extended until August 2016. A new five-year programme has been added on the identification of genes for resistance to stalk rot (Fusarium spp) in maize. Evogene will provide Monsanto with candidate genes and Monsanto will have exclusive rights to commercialise them as part of its maize trait pipeline. The original option for Monsanto to buy 1 million Evogene shares at $12/share has been cancelled in exchange for an increase in milestone payments and royalty rates. A new $12 million put option provides for the sale of shares at market value.

Advertisement
Advertisement

Topics

What to read next

Advertisement
UsernamePublicRestriction

Register

AG000590

Ask The Analyst

Please fill in the form below to send over your enquiry or check the Ask The Analyst Page to find out more about the service

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel